Avamys (fluticasone furoate), a new intranasal steroid (INS) manufactured by GlaxoSmithKline (GSK),
Avamys has shown significant improvements in both nasal and ocular symptoms in adult and adolescent patients with seasonal allergic rhinitis (SAR).
Avamys has also demonstrated improvement in health-related quality of life domains, including eye and sleep related improvements.
Avamys is an easy and effective treatment to use, thanks to an award-winning spray device* which ensures comfort, a consistent dose, little or no drip down throat/nose and minimal or no aftertaste.
Avamys offers symptom relief for 24 hours at a time.1 A clinical study has shown preference for fluticasone furoate (Avamys) compared to fluticasone propionate (Flixonase) by patients with allergic rhinitis with respect to sensory attributes such as odour, taste, dripping down the throat, and nose runoff following single-dose administration.
Studies have shown that fluticasone furoate has low systemic bio availability, rapid clearance from the systemic circulation and 99% plasma protein binding, minimising systemic exposure to the 'free' drug
Avamys is generally well tolerated, with types of side effects that are typical of the INS class of medicines.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment